Arun Kumar Arumugam Raajasekar, MD
Hematology/Oncology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 1 carrier
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health · Stanford Health Care · Yuma Regional Medical Center. That is not proof they admit you there this week.
Plans that list them
2 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Raajasekar’s office at (650) 988-8338 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Yuma Regional Medical CenterYuma, AZAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Yuma Regional Medical CenterPatients rate it 3 of 5 · 63% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 223.03 (174.74 to 271.32) · 70 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.118, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Yuma Regional Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 2 worse of 8 measures. Safety: 1 better, 7 the same, 0 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 223.03 (174.74 to 271.32) · 70 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.118 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.49 (0.53 to 2.45) · 1,120 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 4 · 84 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 11.8 · 154 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 302 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 627 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 16 · 296 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.8 · 3,722 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.42) · 5,914 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.42) · 6,115 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.42 (0.37 to 4.48) · 1,577 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.43 (0 to 3.04) · 438 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.1 (0.65 to 3.55) · 1,494 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.77 (3.99 to 17.55) · 451 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.6 (1.75 to 9.45) · 415 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.16 to 3.1) · 329 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.37 (0 to 1.06) · 4,890 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 26 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.765 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.901 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.621 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.825 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.4 · 405 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.8 · 661 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -9.4 · 291 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.5 · 506 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 644 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 939 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.3) · 327 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.8 to 15.8) · 327 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.1 · 216 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (11.2 to 17.3) · 2,778 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.4) · 940 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,342 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 70% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 66% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 63% |
| Staff "always" explained possible side effects | 39% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$135,723
Medicare paid this office $135,723 for 434 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 158 | $55,203 | $108 |
| Return visit (30+ min) | 279 | $45,532 | $68 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 291 | $10,138 | $13 |
| New patient visit (60+ min) | 70 | $9,173 | $131 |
| Short return visit (20+ min) | 109 | $6,145 | $44 |
See all 8 services
| Long return visit (40+ min) | 158 | $55,203 | $108 |
| Return visit (30+ min) | 279 | $45,532 | $68 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 291 | $10,138 | $13 |
| New patient visit (60+ min) | 70 | $9,173 | $131 |
| Short return visit (20+ min) | 109 | $6,145 | $44 |
| New patient visit (45+ min) | 38 | $3,813 | $100 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,259 | $133 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,213 | $61 |
Who their Medicare patients are
434 Original Medicare patients in 2024. Average age 77 · Women 36% · Also on Medicaid 13% · Health risk score 1.98. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Cancer 60% · Chronic kidney disease 36% · Diabetes 35% · Coronary heart disease 35% · Heart failure 24% · COPD 22% · Atrial fibrillation 21% · Depression 20% · Stroke 13% · Dementia 8%.
The office billed $291,408, Medicare allowed $180,170 and paid $135,723; for 2,303 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 434 | 2,303 | 77 | 1.98 | $291,408 | $135,723 |
| 2023 | 383 | 1,169 | 77 | 2.01 | $198,893 | $93,074 |
| 2022 | 383 | 1,282 | 75 | 1.90 | $237,313 | $109,707 |
| 2021 | 378 | 1,317 | 75 | 2.03 | $243,443 | $114,908 |
| 2020 | 285 | 948 | 75 | 1.94 | $157,843 | $71,183 |
| 2019 | 151 | 282 | 75 | 1.84 | $48,865 | $22,478 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 227 | $41,705 | $71 |
| Long return visit (40+ min) | 112 | $27,480 | $107 |
| New patient visit (60+ min) | 60 | $8,238 | $137 |
| Short return visit (20+ min) | 120 | $7,815 | $47 |
| New patient visit (45+ min) | 53 | $5,162 | $97 |
2022: 5 services
| Long return visit (40+ min) | 134 | $54,382 | $110 |
| Return visit (30+ min) | 207 | $27,016 | $71 |
| New patient visit (60+ min) | 87 | $11,546 | $133 |
| Short return visit (20+ min) | 148 | $9,297 | $44 |
| New patient visit (45+ min) | 27 | $2,715 | $101 |
2021: 9 services
| Long return visit (40+ min) | 159 | $51,118 | $114 |
| Return visit (30+ min) | 207 | $28,838 | $72 |
| New patient visit (60+ min) | 79 | $11,097 | $140 |
| Short return visit (20+ min) | 144 | $10,520 | $50 |
| New patient visit (45+ min) | 38 | $3,503 | $92 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,472 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,215 | $158 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 15 | $691 | $26 |
| Short return visit | 13 | $373 | $29 |
2020: 9 services
| Return visit (30+ min) | 168 | $23,157 | $60 |
| Long return visit (40+ min) | 105 | $17,816 | $88 |
| New patient visit (60+ min) | 87 | $11,241 | $129 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,334 | $161 |
| New patient visit (45+ min) | 41 | $3,914 | $95 |
| Telephone medical discussion with physician, 21-30 minutes | 51 | $3,706 | $63 |
| Short return visit (20+ min) | 60 | $2,705 | $38 |
| Telephone medical discussion with physician, 11-20 minutes | 33 | $1,432 | $40 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $802 | $57 |
2019: 5 services
| Return visit (30+ min) | 57 | $6,422 | $62 |
| Long return visit (40+ min) | 56 | $5,830 | $87 |
| New patient visit (60+ min) | 37 | $4,879 | $132 |
| New patient visit (45+ min) | 18 | $1,819 | $101 |
| Short return visit (20+ min) | 24 | $1,081 | $40 |
Medicaid work
$44,397 in 2024
Medicaid paid $44,397 for 2,538 billed services this clinician did in 2024, up to 50 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 351 | $23,468 |
| Return visit (30+ min) | 453 | $16,236 |
| Short return visit (20+ min) | 144 | $4,376 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 150 | $317 |
| Pain severity quantified; no pain present (COA) (ONC) | 466 | $0 |
| Medication list documented in medical record (COA) | 205 | $0 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 17 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 232 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 43 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 100 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 323 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 54 | $0 |
| 2024 | 2,538 | 12 | 50 | $44,397 |
| 2023 | 2,104 | 9 | 46 | $39,091 |
| 2022 | 1,361 | 9 | 38 | $39,064 |
| 2021 | 667 | 4 | 32 | $26,696 |
| 2020 | 185 | 2 | 26 | $6,920 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 486 | $19,167 |
| Long return visit (40+ min) | 226 | $14,786 |
| Short return visit (20+ min) | 197 | $5,138 |
| Pain severity quantified; no pain present (COA) (ONC) | 412 | $0 |
| Medication list documented in medical record (COA) | 143 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 237 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 12 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 38 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 353 | $0 |
2022
| Long return visit (40+ min) | 395 | $24,470 |
| Return visit (30+ min) | 290 | $9,385 |
| Short return visit (20+ min) | 215 | $5,209 |
| Pain severity quantified; no pain present (COA) (ONC) | 49 | $0 |
| Medication list documented in medical record (COA) | 67 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 108 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 12 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 210 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 15 | $0 |
2021
| Long return visit (40+ min) | 245 | $13,414 |
| Return visit (30+ min) | 247 | $9,117 |
| Short return visit (20+ min) | 159 | $3,011 |
| New patient visit (45+ min) | 16 | $1,155 |
2020
| Return visit (30+ min) | 171 | $6,800 |
| Short return visit (20+ min) | 14 | $120 |
Drugs they prescribed that Part D paid
$4,976,642
Pharmacies billed $4,976,642 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (52 of 1,530) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
1,215 generic and fewer than 11 brand-name prescriptions · $4,976,642 in drug cost · 61 antibiotic prescriptions to 50 people · 25 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 130 | $1,768,259 | $13,602 |
| Cabometyx | 46 | $1,101,174 | $23,939 |
| Pomalyst | 15 | $357,020 | $23,801 |
| Abiraterone Acetate | 147 | $269,289 | $1,832 |
| Nubeqa | 17 | $230,872 | $13,581 |
See all 34 drugs
| Xtandi | 130 | $1,768,259 | $13,602 |
| Cabometyx | 46 | $1,101,174 | $23,939 |
| Pomalyst | 15 | $357,020 | $23,801 |
| Abiraterone Acetate | 147 | $269,289 | $1,832 |
| Nubeqa | 17 | $230,872 | $13,581 |
| Inlyta | 11 | $213,626 | $19,421 |
| Eliquis | 26 | $15,797 | $608 |
| Enoxaparin | 11 | $2,457 | $223 |
| Prochlorperazine Maleate | 133 | $1,793 | $13 |
| Ondansetron | 119 | $1,735 | $15 |
| Prednisone | 155 | $1,116 | $7 |
| Dexamethasone | 61 | $1,102 | $18 |
| Potassium Chloride | 21 | $946 | $45 |
| Hydroxyurea | 28 | $772 | $28 |
| Triamcinolone Acetonide | 14 | $647 | $46 |
| Tamsulosin | 14 | $618 | $44 |
| Oxybutynin Chloride Er | 22 | $399 | $18 |
| Olanzapine | 25 | $338 | $14 |
| Oxycodone | 33 | $336 | $10 |
| Venlafaxine Hcl Er | 14 | $267 | $19 |
| Famotidine | 24 | $259 | $11 |
| Duloxetine | 13 | $229 | $18 |
| Diphenoxylate-Atropine | 15 | $229 | $15 |
| Bicalutamide | 11 | $225 | $20 |
| Acyclovir | 14 | $217 | $16 |
| Levothyroxine | 26 | $200 | $8 |
| Nitrofurantoin Mono-Macro | 16 | $192 | $12 |
| Gabapentin | 18 | $171 | $10 |
| Lidocaine Hcl Viscous | 20 | $145 | $7 |
| Sertraline | 34 | $135 | $4 |
| Levofloxacin | 24 | $88 | $4 |
| Losartan | 13 | $53 | $4 |
| Furosemide | 11 | $50 | $5 |
| Folic Acid | 14 | $41 | $3 |
Year by year
| 2024 | 1,530 | 268 | 3% (52) | None | $4,976,642 |
| 2023 | 1,278 | 212 | 4% (52) | None | $5,154,057 |
| 2022 | 884 | 158 | 5% (40) | None | $2,192,983 |
| 2021 | 572 | 109 | 2% (12) | 17% | $1,441,767 |
| 2020 | 482 | 83 | None | 13% | $999,483 |
| 2019 | 112 | 43 | None | 13% | $140,498 |
| 2018 | 47 | 17 | 30% (14) | None | $1,263 |
| 2017 | 92 | 31 | 41% (38) | None | $8,449 |
| 2016 | 63 | 18 | None | None | $5,768 |
| 2015 | 14 | None | None | 0% | $250 |
| 2014 | 11 | None | None | None | $312 |
| 2013 | 25 | 11 | 0% (0) | None | $4,638 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 28 drugs
| Xtandi | 120 | $1,683,897 | $14,032 |
| Cabometyx | 29 | $693,796 | $23,924 |
| Abiraterone Acetate | 131 | $587,418 | $4,484 |
| Pomalyst | 22 | $506,821 | $23,037 |
| Inlyta | 17 | $330,058 | $19,415 |
| Revlimid | 12 | $224,671 | $18,723 |
| Afinitor | 11 | $214,960 | $19,542 |
| Jakafi | 11 | $196,394 | $17,854 |
| Nubeqa | 15 | $173,234 | $11,549 |
| Eliquis | 24 | $24,836 | $1,035 |
| Imatinib Mesylate | 14 | $18,445 | $1,318 |
| Ondansetron | 125 | $2,104 | $17 |
| Prochlorperazine Maleate | 116 | $1,873 | $16 |
| Dexamethasone | 56 | $1,036 | $18 |
| Prednisone | 116 | $910 | $8 |
| Oxycodone | 36 | $561 | $16 |
| Potassium Chloride | 11 | $557 | $51 |
| Hydroxyurea | 24 | $520 | $22 |
| Gabapentin | 13 | $454 | $35 |
| Tamsulosin | 15 | $276 | $18 |
| Pantoprazole | 14 | $220 | $16 |
| Famotidine | 18 | $204 | $11 |
| Levothyroxine | 11 | $197 | $18 |
| Acyclovir | 13 | $190 | $15 |
| Omeprazole | 16 | $147 | $9 |
| Sertraline | 24 | $145 | $6 |
| Levofloxacin | 15 | $112 | $7 |
| Sulfamethoxazole-Trimethoprim | 24 | $62 | $3 |
2022: 24 drugs
| Pomalyst | 24 | $502,628 | $20,943 |
| Xtandi | 26 | $355,964 | $13,691 |
| Revlimid | 14 | $271,697 | $19,407 |
| Abiraterone Acetate | 52 | $247,527 | $4,760 |
| Nubeqa | 17 | $231,418 | $13,613 |
| Scemblix | 11 | $218,585 | $19,871 |
| Imatinib Mesylate | 23 | $17,099 | $743 |
| Eliquis | 21 | $14,921 | $711 |
| Ondansetron | 97 | $2,439 | $25 |
| Dexamethasone | 85 | $2,263 | $27 |
| Prochlorperazine Maleate | 97 | $1,718 | $18 |
| Prednisone | 68 | $675 | $10 |
| Bicalutamide | 16 | $590 | $37 |
| Potassium Chloride | 13 | $546 | $42 |
| Hydroxyurea | 20 | $378 | $19 |
| Oxycodone | 29 | $352 | $12 |
| Acyclovir | 23 | $292 | $13 |
| Fluconazole | 13 | $255 | $20 |
| Gabapentin | 14 | $166 | $12 |
| Omeprazole | 15 | $135 | $9 |
| Levofloxacin | 11 | $131 | $12 |
| Sertraline | 11 | $127 | $12 |
| Famotidine | 18 | $85 | $5 |
| Sulfamethoxazole-Trimethoprim | 15 | $39 | $3 |
2021: 13 drugs
| Revlimid | 30 | $494,833 | $16,494 |
| Abiraterone Acetate | 41 | $245,243 | $5,982 |
| Xtandi | 16 | $205,260 | $12,829 |
| Votrient | 12 | $124,468 | $10,372 |
| Imatinib Mesylate | 24 | $22,919 | $955 |
| Dexamethasone | 56 | $1,488 | $27 |
| Ondansetron | 50 | $888 | $18 |
| Prochlorperazine Maleate | 49 | $634 | $13 |
| Hydroxyurea | 18 | $573 | $32 |
| Prednisone | 38 | $377 | $10 |
| Pantoprazole | 23 | $336 | $15 |
| Acyclovir | 17 | $209 | $12 |
| Omeprazole | 16 | $79 | $5 |
2020: 11 drugs
| Revlimid | 19 | $287,281 | $15,120 |
| Xtandi | 20 | $246,989 | $12,349 |
| Abiraterone Acetate | 50 | $210,584 | $4,212 |
| Votrient | 12 | $116,053 | $9,671 |
| Imatinib Mesylate | 13 | $14,540 | $1,118 |
| Dexamethasone | 47 | $1,050 | $22 |
| Ondansetron | 32 | $844 | $26 |
| Prochlorperazine Maleate | 32 | $548 | $17 |
| Prednisone | 60 | $435 | $7 |
| Famotidine | 16 | $159 | $10 |
| Levofloxacin | 12 | $117 | $10 |
2019: 2 drugs
| Prochlorperazine Maleate | 11 | $126 | $11 |
| Prednisone | 12 | $73 | $6 |
2017: 1 drug
| Morphine Sulfate Er | 13 | $766 | $59 |
Money from drug and device companies
$942 in 2025
| 2025 | 1 | 2 | $942 | $942 |
| 2023 | 2 | 2 | None | $95 |
| 2022 | 1 | 1 | None | $62 |
| 2021 | 1 | 1 | None | $20 |
| 2019 | 1 | 1 | None | $21 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| TerSera Therapeutics | Margenza | $942 | 2 payments
|
See all 2 published payments
| TerSera Therapeutics | Consulting · 2025-03-11 | Margenza | $628 |
| TerSera Therapeutics | Consulting · 2025-02-10 | Margenza | $314 |
See earlier years (2023, 2022, 2021, 2019)
2023: $95
| AstraZeneca Pharmaceuticals LP | Lynparza | $71 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $24 | 1 payment
|
2022: $62
| Janssen Biotech | Darzalex | $62 | 1 payment
|
2021: $20
| Kite Pharma | None | $20 | 1 payment
|
2019: $21
| Genzyme | Cablivi | $21 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2025 | Their institution | $68,070 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Phase III Multi-Center Study of Azacitidine With Or Without Mbg453 for the Treatment of Patients With Intermediate, High Or Very High Risk Myelodysplastic Syndrome (Mds) As Per Ipss-R, Or Chronic Myelomonocytic Leukemia-2 (Cmml-2) · 2023 | Their institution | $59,983 |
| AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2024 | Their institution | $49,639 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Phase III Multi-Center Study of Azacitidine With Or Without Mbg453 for the Treatment of Patients With Intermediate, High Or Very High Risk Myelodysplastic Syndrome (Mds) As Per Ipss-R, Or Chronic Myelomonocytic Leukemia-2 (Cmml-2) · 2024 | Their institution | $44,338 |
| AstraZeneca Pharmaceuticals LP · A Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination With Tremelimumab Lenvatinib Given Concurrently With Transarterial Chemoembolization (Tace) Compared To Tace Alone in Patients With Locoregional Hepatocellular Carcinoma (Emerald-3) · 2025 | Their institution | $35,184 |
| Janssen Research & Development, LLC · Biomarker Study To Determine Frequency of Dna Repair Defects in Men With Metastatic Prostate Cancer · 2021 | Their institution | $27,434 |
| AstraZeneca Pharmaceuticals LP · A Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination With Tremelimumab Lenvatinib Given Concurrently With Transarterial Chemoembolization (Tace) Compared To Tace Alone in Patients With Locoregional Hepatocellular Carcinoma (Emerald-3) · 2023 | Their institution | $23,969 |
| AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2023 | Their institution | $22,382 |
| AstraZeneca Pharmaceuticals LP · A Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination With Tremelimumab Lenvatinib Given Concurrently With Transarterial Chemoembolization (Tace) Compared To Tace Alone in Patients With Locoregional Hepatocellular Carcinoma (Emerald-3) · 2024 | Their institution | $18,297 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Phase III Multi-Center Study of Azacitidine With Or Without Mbg453 for the Treatment of Patients With Intermediate, High Or Very High Risk Myelodysplastic Syndrome (Mds) As Per Ipss-R, Or Chronic Myelomonocyt · 2025 | Their institution | $12,597 |
| Janssen Research & Development, LLC · Biomarker Study To Determine Frequency of Dna Repair Defects in Men With Metastatic Prostate Cancer · 2023 | Their institution | $2,000 |
| Janssen Research & Development, LLC · Biomarker Study To Determine Frequency of Dna Repair Defects in Men With Metastatic Prostate Cancer · 2022 | Their institution | $1,163 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 82.4 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1801143722
- Licence
- KY 49139
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2400 S Avenue A, Yuma, AZ, 85364
- NPI first listed
- 2012-08-09
- NPI last updated
- 2026-02-12
- NPI record certified
- 2026-02-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 815 Pollard Rd, Los Gatos, CA, 95032